Clinical Data Data could move J&J’s Talvey earlier in myeloma therapy PharmaphorumJohnson Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.HematologyRead full story pharminent June 15, 2026 (Last updated: June 15, 2026) Pharmaphorum Johnson Johnson’s Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026. Hematology Read full story Post navigation Previous: FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatmentNext: Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026